Methylin is owned by Specgx Llc.
Methylin contains Methylphenidate Hydrochloride.
Methylin has a total of 1 drug patent out of which 0 drug patents have expired.
Methylin was authorised for market use on 19 December, 2002.
Methylin is available in solution;oral dosage forms.
The generics of Methylin are possible to be released after 07 October, 2024.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7691880||SPECGX LLC||Methylphenidate solution and associated methods of administration and production|| |
(1 year, 7 months from now)
Market Authorisation Date: 19 December, 2002
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic